Mark Gaffney, Chief Executive Officer of Calluna Pharma, said: “It has been a rapid and impressive start to our journey as Calluna Pharma following joining forces of Oxitope Pharma and Arxx ...

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 ...

Calluna Pharma Successfully Completes Phase 1 Clinical Study of CAL101, a First-in-Class Therapeutic for Fibrotic and Fibro-Inflammatory Indications CAL101 is an anti-S100A4 monoclonal antibody ...

It has been a rapid and impressive start to our journey as Calluna Pharma following joining forces of Oxitope Pharma and Arxx Therapeutics, two key players in the innate immunology space. I am ...